Alexza Pharmaceuticals Inc.
2091 Stierlin Court
Mountain View,
CA 94043
United States - Map
Phone: 650-944-7000
Fax: 650-944-7999
Web Site: http://www.alexza.com
| Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches. Its products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the companys single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. The company was founded in 2000 and is based in Mountain View, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Thomas B. King , 54
Chief Exec. Officer, Pres |
$
542.00K |
$
1.25M | Mr. August J. Moretti J.D.,
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec. |
$
367.00K |
$
61.00K | Mr. Michael J. Simms , 47
Sr. VP of Operations & Manufacturing |
$
305.00K | N/A | Dr. James V. Cassella Ph.D., 54
Sr. VP of R&D |
N/A
| N/A | Mr. Anthony Gordon Tebbutt , 61
Consultant |
$
366.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.50% Nasdaq 
0.03 (1.36%) 
Profile
